Company news: Pfizer and Bristol-Myers Squibb

Share this article:

The FDA granted priority review status to Eliquis (apixaban), the novel oral anticoagulant being developed by Pfizer and Bristol-Myers Squibb, the firms said. The PDUFA goal date for a decision by the FDA is March 28, 2012.

The FDA issued a draft Blueprint for educating doctors on opioid drugs including long-acting and extended-release brand name and generic products. The blueprint contains core messages intended for use by continuing education providers to develop educational materials to train prescribers under the required risk evaluation and mitigation strategy (REMS) for these products. The FDA is seeking stakeholder input on the document until December 7.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.